ALKS

ALKS 4230

Solid Tumors

Phase 2 Readout

Exp Date

September 2021

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: ALKS 4230 for Solid Tumors Phase 3 Readout

  • Clinical Trial (NCT02799095): A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors


WHAT IS THE NEXT CATALYST EVENT?

  • Phase 2 Readout 


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • September 2021


PRIOR DATA/EVENTS

PRESS RELEASES

MECHANISM OF ACTION 

  • ALKS 4230 is an investigational, novel, engineered fusion protein comprised of modified interleukin-2 (IL-2) and the high affinity IL-2 alpha receptor chain, designed to selectively expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by preferentially binding to the intermediate-affinity IL-2 receptor complex. The selectivity of ALKS 4230 is designed to leverage the proven antitumor effects of existing IL-2 therapy while mitigating certain limitations.

Updated by MV

ALKS 4230, ALKS, Alkermes, solid tumors, cancer, oncology 

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon